This is an X-PIL, which is a text only patient information leaflet, designed for people with sight problems.
Table of Contents
Activelle® 1 mg/0.5 mg film-coated tablets
estradiol/norethisterone acetate
1.What Activelle® is and what it is used for 2 Before you take Activelle® 3.How to use Activelle® 4 Possible side effects 5.How to store Activelle® 6. Further information
Activelle® is a continuous combined Hormone Replacement Therapy (HRT). It contains the hormones estradiol and norethisterone acetate. Activelle® is suitable for postmenopausal women with at least 1 year since their last natural period.
The tablets contain 2 hormones: estradiol 1 mg (an oestrogen identical to the one made in the ovaries) and norethisterone acetate 0.5 mg (a progestagen that acts in a similar way to the body’s own hormone progesterone).
Activelle® is prescribed for women who have not had their womb removed, and whose periods stopped more than a year ago.
The experience of treating women older than 65 years is limited.
Before you start taking Activelle® , your doctor will inform you about the risks and benefits of the treatment (see also section 4 Other side effects of combined HRT). Before you start treatment and regularly during treatment, your doctor will evaluate whether Activelle® is the right treatment for you. Your doctor will perform a physical examination. This includes an examination of your breasts, and may include an examination of your abdomen or an internal examination. Your doctor will tell you how often you should go for periodic check-ups, taking into account your general state of health. If you have any close relatives (mother, sister, maternal or paternal grandmother), who has suffered from serious illness, e.g. blood clot or breast cancer, you might be at an increased risk of developing the illness. You should therefore always tell your doctor about any close relatives suffering from a serious illness, and you should also tell your doctor about any changes, you might find in your breasts.
Once you have started on Activelle® , you should see your doctor for regular check-ups (at least once a year). At these checkups, your doctor may discuss the benefits and risks of continuing with Activelle® .
As well as regular check-ups with your doctor, be sure to:
If any of the following applies to you, talk to your doctor. Do not start taking Activelle® :
If you have (or have had) any of the following conditions, tell your doctor. He or she may want to see you more often for check-ups.
These conditions may in rare cases come back or get worse during treatment with Activelle® :
If you need a blood test, tell your doctor that you are taking Activelle® since oestrogen can affect the results of certain laboratory tests.
If you are going to have surgery, talk to your doctor. You may need to stop taking these tablets 4 to 6 weeks before the operation to reduce the risk of a blood clot. Your doctor will tell you when you can start again.
If you are experiencing any of the following conditions below, stop taking Activelle® and contact your doctor immediately:
Excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of the womb (endometrial cancer)
In women with an intact womb taking oestrogen-only HRT over a long period of time, the risk of excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the womb lining (endometrial cancer) is increased.
Taking a progestagen in addition to the oestrogen, as in Activelle® , protects you from this extra risk.
Compare
In women who still have a womb and who are not taking HRT, on average 5 in 1,000 will be diagnosed with endometrial cancer.
For women who still have a womb and take oestrogen-only HRT, the number of extra cases could vary between 5 and 55 in 1,000 users between the ages of 50 and 65 depending on the dose and for how long it is taken.
The addition of a progestagen to oestrogen-only HRT substantially reduces the risk of endometrial cancer.
Breast cancer
Evidence suggests that taking combined oestrogen-progestagen and possibly also oestrogen-only HRT increases the risk of breast cancer.
The extra risk depends on how long you take HRT. The additional risk is visible after about 3 years.
However, it returns to normal within a few years (at most 5) after stopping treatment.
Women aged 50 to 65 who are not taking HRT, on average 9 to 12 in 1,000 will be diagnosed with breast cancer over a 5-year period.
For women aged 50 to 65 who are taking oestrogen-progestagen HRT over 5 years, the number of extra cases will be 6 in 1,000 users. Looking at women aged 50 to 79 who are not taking HRT, on average 14 in 1,000 will be diagnosed with breast cancer over a 5-year period.
For women aged 50 to 79 who are taking oestrogen-progestagen HRT over 5 years, the number of extra cases will be 4 in 1,000 users.
Ovarian cancer
Ovarian cancer is much rarer than breast cancer. A slightly increased risk of ovarian cancer has been reported in women taking HRT for at least 5 to 10 years. Some studies suggest that the long-term use of combined HRT may carry a similar or slightly smaller risk.
For women who have been taking HRT for over 5 years, there will be 1 extra case per 2,500 users.
Blood clots in a vein (venous thromboembolism)
The risk of blood clots in the veins is about 1.3 to 3-times higher in HRT users than in nonusers, especially during the first year of taking it.
Blood clots are not always serious, but if one travels to the lungs, it can cause chest pain, breathlessness, collapse or even death.
You are generally more likely to get a blood clot in your veins if one or more of the following applies to you. Inform your doctor if any of these situations applies to you:
Women in their 50s who are not taking HRT, on average over a 5-year period, 4 in 1,000 would be expected to get a blood clot in a vein.
For women in their 50s who have been taking oestrogen-progestagen HRT for over 5 years, the number of extra cases will be 5 in 1,000 users.
Heart disease (heart attack)
There is no evidence that HRT will help to prevent a heart attack.
Women over the age of 60 years who use oestrogen-progestagen HRT are slightly more likely to develop heart disease than those not taking any HRT.
Stroke
The risk of getting stroke is about 1.5-times higher in HRT users than in non-users. The risk of stroke strongly depends on age.
Therefore, the number of extra cases of stroke due to use of HRT will rise with more advanced age.
For women in their 50s who are taking HRT, the number of extra cases will be 3 in 1,000 users over 5 years.
HRT will not prevent memory loss. The risk of probable memory loss may be somewhat higher in women who start using any kind of HRT after the age of 65.
Some medicines may reduce the effects of Activelle® :
Other medicines may increase the effects of Activelle® :
Concomitant administration of cyclosporine may cause increased blood levels of cyclosporine.
Please tell your doctor or pharmacist, if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, herbal medicines or other natural products.
The tablets can be taken with or without food and drink.
Pregnancy: You should not take Activelle® if you are pregnant. If you become pregnant stop taking Activelle® immediately and contact your doctor.
Breast-feeding: You should not use Activelle® if you are breast-feeding.
Activelle® has no known effect on the ability to drive or use machines.
Activelle® contains lactose monohydrate. If you have an intolerance to some sugars, contact your doctor before taking Activelle® .
Always take Activelle® exactly as your doctor has told you. Check with your doctor or pharmacist if you are unsure.
Take one tablet once a day, at about the same time each day. Take the tablet with a glass of water.
Take a tablet every day without stopping. After you have used all 28 tablets in a calendar pack, go straight to using the next pack.
See USER INSTRUCTIONS at the end of the package leaflet
You may start treatment with Activelle® on any convenient day. However, if you are switching from an HRT product when you have monthly bleeding, start your treatment straight after the bleeding has ended.
Your doctor should aim to prescribe the lowest dose for the shortest time that gives you relief from your symptoms. Talk to your doctor if your symptoms are not better after 3 months.
If you have taken more Activelle® than you should, talk to a doctor or pharmacist. An overdose of Activelle® could make you feel sick or vomit.
If you forget to take your tablet at the usual time, take it within the next 12 hours. If more than 12 hours have gone by, start again as normal the next day. Do not take a double dose to make up for a forgotten tablet.
Forgetting a dose may increase the likelihood of breakthrough bleeding and spotting if you still have your womb.
If you would like to stop taking Activelle® , talk to your doctor first. He/she will explain the effects of stopping treatment and discuss other possibilities with you.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Activelle® can have side effects, although not everybody gets them.
(uncommon side effect – affects 1 to 10 users in 1,000)
Though it is an uncommon event, hypersensitivity/allergy may occur. Signs of hypersensitivity/allergy may include one or more of the following symptoms: hives, itching, swelling, difficulty in breathing, low blood pressure (paleness and coldness of skin, rapid heart beat), feeling dizzy, sweating, which could be signs of anaphylactic reaction/shock. If one of the mentioned symptoms appears, stop taking Activelle® and seek immediate medical help.
Activelle® will not cause regular monthly bleeding. When first starting the tablets, some women experience slight vaginal bleeding or spotting.
If you get breakthrough bleeding or spotting, it is usually nothing to worry about, especially during the first few months of taking HRT. However, contact your doctor as soon as possible:
Your doctor may ask you about any vaginal bleeding with Activelle® at your regular check-ups. You may find it helpful to make a note of any bleeding in your diary.
The frequency of possible side effects listed below is defined using the following convention:
Very common (affects more than 1 user in 10)
Common (affects 1 to 10 users in 100)
Uncommon (affects 1 to 10 users in 1,000)
Rare (affects 1 to 10 users in 10,000)
Very rare (affects less than 1 user in 10,000)
Not known (frequency cannot be estimated from the available data)
Very common side effects
Common side effects
Uncommon side effects
Rare side effects
Very rare side effects
Women using HRT have a slightly increased risk of developing the following diseases:
For more information about these side effects, see section 2.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Keep out of the reach and sight of children.
Do not use Activelle® after the expiry date, which is stated on the label and outer carton after ‘EXP.’
The expiry date refers to the last day of that month.
Do not store above 25°C.
Do not refrigerate.
Keep the container in the outer carton in order to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
The active substances are estradiol 1 mg (as estradiol hemihydrate) and norethisterone acetate 0.5 mg.
Other ingredients are: lactose monohydrate, maize starch, copovidone, talc and magnesium stearate.
The film-coating contains: hypromellose, triacetin and talc.
The film-coated tablets are white, round with a diameter of 6 mm.
The tablets are imprinted NOVO 288 on one side and the Novo Nordisk logo (an APIS bull) on the other side.
Pack sizes available:
Not all pack sizes may be marketed
While you are receiving this medication, you should see your doctor regularly, at least every 6 to 12 months.
If you have any unusual symptoms such as unexplained pains in the chest, abdomen or legs you must consult your doctor immediately. Patients with a family history of breast cancer should use this medication with great caution.
This medicinal product is authorised in the Member States of the EEA under the following names:
Member States of the EEA:
Activelle® - except for United Kingdom: Kliovance.
This leaflet was last approved in: 10 June 2011
1. Set the day reminder
Turn the inner disc to set the day of the week opposite the little plastic tab.
2. Take the first day’s tablet
Break the plastic tab and tip out the first tablet.
3. Move the dial every day
On the next day, simply move the transparent dial clockwise 1 space as indicated by the arrow. Tip out the next tablet. Remember to take only 1 tablet once a day.
You can only turn the transparent dial after the tablet in the opening has been removed.
Activelle® is a trademark owned by Novo Nordisk FemCare AG Switzerland
© 2011
Novo Nordisk A/S
8-2901-11-042-5
Link to this document from your website:http://www.medicines.ie/medicine/14523/XPIL/Activelle/